

Office for Research The Royal Melbourne Hospital Level 2 South West 300 Grattan Street Parkville VIC 3050 Australia

Telephone: +61 3 9342 8530 Facsimile: +61 3 9342 8548 Email: research@mh.org.au

thermh.org.au ABN 73 802 706 972



Ethical Approval

Royal Melbourne Hospital Human Research Ethics Committee

A/Prof Kelly Allott

Orygen, The National Centre of Excellence in Youth Mental Health

16 February 2023

Dear A/Prof Kelly Allott,

HREC Reference Number: HREC/89942/MH-2022

Royal Melbourne Hospital Site Reference Number: 2022.275

Project Title: CogScreen: Validating cognitive screening in young people with first-episode psychosis

I am pleased to advise that the above project has **received ethical approval** from the Royal Melbourne Hospital Human Research Ethics Committee (HREC). The HREC confirms that your proposal meets the requirements of the National Statement on Ethical Conduct in Human Research (2007). This HREC is organised and operates in accordance with the National Health and Medical Research Council's (NHRMC) National Statement on Ethical Conduct in Human Research (2007), and all subsequent updates, and in accordance with the Note for Guidance on Good Clinical Practice (CPMP/ICH/135/95), the Health Privacy Principles described in the Health Records Act 2001 (Vic) and Section 95A of the Privacy Act 1988 (and subsequent Guidelines).

HREC Approval Date: 15 February 2023

Ethical approval for this project applies at the following sites:

Site

- Orygen Specialist Program, Royal Melbourne Hospital VIC
- headspace Early Psychosis (Alfred Health) VIC
- headspace Early Psychosis (Adelaide) SA
- Western/Eastern/Northern/North Eastern Community Mental Health Adelaide (formerly summarised as North Adelaide Local Health Network and Central Adelaide Local Health Network)
- Prevention Early Intervention and Recovery Service (PEIRS) (Western Sydney Local Health District) NSW
- headspace Early Psychosis Service (Parramatta and Mt Druitt) NSW
- Bondi Early Psychosis Program (EPP) (South-Eastern Local Health District) NSW

Approved Documents:

The following documents have been reviewed and approved:

Document	Version	Date
Protocol	2.1	15 February 2023
Brief Study Summary	2.0	01 February 2023
Master Self Participant Information Sheet/Consent Form	2.1	15 February 2023
Master Parent/Guardian Participant Information	2.1	15 February 2023
Sheet/Consent Form		
Master Self Implementation Participant Information	2.1	15 February 2023
Sheet/Consent Form		
Master Parent/Guardian Implementation Participant	2.1	15 February 2023
Information Sheet/Consent Form		

Master Parent/Guardian Withdrawal Form 1.0 20 September 2022 Mandatory Decision Making Flow Chart VIC 1.0 31 January 2023 Cognitive Test Results Summary 12-15 2.0 31 January 2023 Example SMS 1.0 15 November 2022 Guidelines for Interpreters Completing Research Assessments (20 guidelines for Researchers Completing Research Assessments with Interpreters 1.0 31 January 2023 Assessments with Interpreters 2.0 0.1 February 2023 Assessments with Interpreters 2.0 0.1 February 2023 Managing Disclosures of Abuse or Neglect 2.0 31 January 2023 Safety Management Plan 2.0 2.5 January 2023 Post-study Survey 1.0 0.1 November 2022 CogScreen SoA 2.0 0.1 February 2023 Montreal Cognitive Assessment (MoCA) 7.2 - Screen for Cognitive Impairment in Psychiatry (SCIP) 1 - - Screen for Cognitive Impairment in Psychiatry (SCIP) 2 - - SciD-5 Diagnoses 1.0 0.9 May 2018 Acceptability Questionnaire 1.0 2.0 October 2022 A	Master Self Withdrawal Form	1.0	20 September 2022
Mandatory Decision Making Flow Chart VIC 1.0 31 January 2023 Cognitive Test Results Summary 12-15 2.0 31 January 2023 Cognitive Test Results Summary 16+ 2.0 31 January 2023 Example SMS 1.0 15 November 2022 Guidelines for Interpreters Completing Research Assessments 1.0 31 January 2023 Guidelines for Researchers Completing Research 1.0 31 January 2023 Assessments with Interpreters			·
Cognitive Test Results Summary 16+ 2.0 31 January 2023 Cognitive Test Results Summary 16+ 2.0 31 January 2023 Example SMS 1.0 15 November 2022 Guidelines for Interpreters Completing Research Assessments 1.0 31 January 2023 Assessments with Interpreters 31 January 2023 Cog Screen Inclusion/Exclusion 2.0 01 February 2023 Managing Disclosures of Abuse or Neglect 2.0 31 January 2023 Safety Management Plan 2.0 25 January 2023 Post-study Survey 1.0 01 November 2022 CogScreen SOA 2.0 01 February 2023 Montreal Cognitive Assessment (MoCA) 7.2 - Screen for Cognitive Impairment in Psychiatry (SCIP) 1 - - Screen for Cognitive Impairment in Psychiatry (SCIP) 2 - - SCID-5 Diagnoses 1.0 09 May 2018 Acceptability Questionnaire 1.0 20 October 2022 ACE 1.0 23 November 2022 AQ 1.2 19 June 2018 ASSIST 1.0 01 February 2023 <td>,</td> <td></td> <td></td>	,		
Cognitive Test Results Summary 16+ 2.0 31 January 2023 Example SMS 1.0 15 November 2022 Guidelines for Interpreters Completing Research Assessments 1.0 31 January 2023 Guidelines for Researchers Completing Research 1.0 31 January 2023 Assessments with Interpreters 2.0 0.1 February 2023 Cog Screen Inclusion/Exclusion 2.0 0.1 February 2023 Managing Disclosures of Abuse or Neglect 2.0 31 January 2023 Safety Management Plan 2.0 0.1 February 2023 Post-study Survey 1.0 0.1 November 2022 CogScreen SOA 2.0 0.1 February 2023 Montreal Cognitive Assessment (MoCA) 7.2 - Screen for Cognitive Impairment in Psychiatry (SCIP) 1 - - Screen for Cognitive Impairment in Psychiatry (SCIP) 2 - - Screen for Cognitive Impairment in Psychiatry (SCIP) 2 - - Screen for Cognitive Impairment in Psychiatry (SCIP) 2 - - Screen for Cognitive Impairment in Psychiatry (SCIP) 2 - - SciD-5 Diagnoses 1.0			•
Example SMS			
Guidelines for Interpreters Completing Research Assessments 1.0 31 January 2023 Guidelines for Researchers Completing Research 1.0 31 January 2023 Assessments with Interpreters 2.0 01 February 2023 Cog Screen Inclusion/Exclusion 2.0 31 January 2023 Managing Disclosures of Abuse or Neglect 2.0 31 January 2023 Safety Management Plan 2.0 25 January 2023 Post-study Survey 1.0 01 November 2022 CogScreen SOA 2.0 01 February 2023 Montreal Cognitive Assessment (MoCA) 7.2 - Screen for Cognitive Impairment in Psychiatry (SCIP) 1 - - Screen for Cognitive Impairment in Psychiatry (SCIP) 2 - - Screen for Cognitive Impairment in Psychiatry (SCIP) 2 - - Screen for Cognitive Impairment in Psychiatry (SCIP) 2 - - Screen for Cognitive Impairment in Psychiatry (SCIP) 2 - - Screen for Cognitive Impairment in Psychiatry (SCIP) 2 - - Screen for Cognitive Impairment in Psychiatry (SCIP) 2 - - SciD-7			
Guidelines for Researchers Completing Research 1.0 31 January 2023			
Assessments with Interpreters			•
Cog Screen Inclusion/Exclusion 2.0 01 February 2023 Managing Disclosures of Abuse or Neglect 2.0 31 January 2023 Safety Management Plan 2.0 25 January 2023 Post-study Survey 1.0 01 November 2022 CogScreen SOA 2.0 01 February 2023 Montreal Cognitive Assessment (MoCA) 7.2 - Screen for Cognitive Impairment in Psychiatry (SCIP) 1 - - Screen for Cognitive Impairment in Psychiatry (SCIP) 2 - - SCID-5 Diagnoses 1.0 09 May 2018 Acceptability Questionnaire 1.0 20 October 2022 ACE 1.0 23 November 2022 AQ 1.2 19 June 2018 ASRS 1.0 01 February 2023 ASSIST 1.0 01 February 2023 Demographics 1.0 21 December 2016 CSS 1.0 18 October 2022 Functioning Probes 1.0 01 February 2023 GAD-7 1.0 18 July 2017 GF Role 1.0 01 February 2023			
Managing Disclosures of Abuse or Neglect 2.0 31 January 2023 Safety Management Plan 2.0 25 January 2023 Post-study Survey 1.0 01 November 2022 CogScreen SOA 2.0 01 February 2023 Montreal Cognitive Assessment (MoCA) 7.2 - Screen for Cognitive Impairment in Psychiatry (SCIP) 1 - - Screen for Cognitive Impairment in Psychiatry (SCIP) 2 - - SCID-5 Diagnoses 1.0 09 May 2018 Acceptability Questionnaire 1.0 20 October 2022 AQ 1.2 19 June 2018 ASRS 1.0 01 February 2023 ASSIST 1.0 02 August 2016 BPNS 1.0 21 December 2016 CSS 1.0 18 October 2022 Demographics 1.0 01 November 2022 Functioning Probes 1.0 01 February 2023 GAD-7 1.0 18 July 2017 GF Role 1.0 01 February 2023 GESS 1.0 01 February 2023 <td< td=""><td></td><td>2.0</td><td>01 February 2023</td></td<>		2.0	01 February 2023
Safety Management Plan 2.0 25 January 2023 Post-study Survey 1.0 01 November 2022 CogScreen SOA 2.0 01 February 2023 Montreal Cognitive Assessment (MoCA) 7.2 - Screen for Cognitive Impairment in Psychiatry (SCIP) 1 - - Screen for Cognitive Impairment in Psychiatry (SCIP) 2 - - SCID-5 Diagnoses 1.0 09 May 2018 Acceptability Questionnaire 1.0 20 October 2022 ACE 1.0 23 November 2022 AQ 1.2 19 June 2018 ASSRS 1.0 01 February 2023 ASSIST 1.0 02 August 2016 BPNS 1.0 02 August 2016 BPNS 1.0 18 October 2022 Demographics 1.0 18 October 2022 Functioning Probes 1.0 01 November 2022 Functioning Probes 1.0 01 February 2023 GF Role 1.0 01 February 2023 GFS Social 1.0 01 February 2023 GFSES 1.0 01 February 2023 Implementation Interview Gui			•
Post-study Survey 1.0 01 November 2022 CogScreen SOA 2.0 01 February 2023 Montreal Cognitive Assessment (MoCA) 7.2 - Screen for Cognitive Impairment in Psychiatry (SCIP) 1 - - Screen for Cognitive Impairment in Psychiatry (SCIP) 2 - - SCID-5 Diagnoses 1.0 09 May 2018 Acceptability Questionnaire 1.0 23 November 2022 ACE 1.0 23 November 2022 AQ 1.2 19 June 2018 ASRS 1.0 01 February 2023 ASSIST 1.0 02 August 2016 BPNS 1.0 21 December 2016 CSS 1.0 18 October 2022 Demographics 1.0 01 November 2022 Functioning Probes 1.0 01 November 2022 GAD-7 1.0 18 July 2017 GF Role 1.0 01 February 2023 GFSES 1.0 01 February 2023 GSES 1.0 01 February 2023 MSSR-VF 1.0 01 F			
CogScreen SOA 2.0 01 February 2023 Montreal Cognitive Assessment (MoCA) 7.2 - Screen for Cognitive Impairment in Psychiatry (SCIP) 1 - - Screen for Cognitive Impairment in Psychiatry (SCIP) 2 - - SCID-5 Diagnoses 1.0 09 May 2018 Acceptability Questionnaire 1.0 20 October 2022 ACE 1.0 23 November 2022 AQ 1.2 19 June 2018 ASRS 1.0 01 February 2023 ASSIST 1.0 02 August 2016 BPNS 1.0 21 December 2016 CSS 1.0 18 October 2022 Functioning Probes 1.0 01 February 2023 GAD-7 1.0 18 July 2017 GF Role 1.0 01 February 2023 GFS Social 1.0 01 February 2023 GSES 1.0 01 February 2023 MSR-VF 1.0 01 February 2023 PANSS 1.1 21 August 2017 NSSR-VF 1.0 01 February 2023 <td></td> <td></td> <td>•</td>			•
Montreal Cognitive Assessment (MoCA) 7.2 - Screen for Cognitive Impairment in Psychiatry (SCIP) 1 - - Screen for Cognitive Impairment in Psychiatry (SCIP) 2 - - SCID-5 Diagnoses 1.0 09 May 2018 Acceptability Questionnaire 1.0 20 October 2022 ACE 1.0 23 November 2022 AQ 1.2 19 June 2018 ASRS 1.0 01 February 2023 ASSIST 1.0 02 August 2016 BPNS 1.0 21 December 2016 CSS 1.0 18 October 2022 Demographics 1.0 18 October 2022 Functioning Probes 1.0 01 February 2023 GAD-7 1.0 18 July 2017 GF Role 1.0 01 February 2023 GSES 1.0 01 February 2023 GSES 1.0 01 February 2023 Implementation Interview Guide 1.0 01 February 2023 PANSS 1.1 26 May 2016 PCL-5 1.1 29 Novemb			
Screen for Cognitive Impairment in Psychiatry (SCIP) 2 - - Screen for Cognitive Impairment in Psychiatry (SCIP) 2 - - SCID-5 Diagnoses 1.0 09 May 2018 Acceptability Questionnaire 1.0 20 October 2022 ACE 1.0 23 November 2022 AQ 1.2 19 June 2018 ASRS 1.0 01 February 2023 ASSIST 1.0 02 August 2016 BPNS 1.0 21 December 2016 CSS 1.0 18 October 2022 Demographics 1.0 01 November 2022 Functioning Probes 1.0 01 February 2023 GAD-7 1.0 18 July 2017 GF Role 1.0 01 February 2023 GFS Social 1.0 01 February 2023 GSES 1.0 01 February 2023 Implementation Interview Guide 1.0 20 October 2022 K10 1.1 21 August 2017 NSSR-VF 1.0 01 February 2023 PANSS 1.1 26 May 2016 PCL-5 1.1 29 November 2022			-
Screen for Cognitive Impairment in Psychiatry (SCIP) 2 - - SCID-5 Diagnoses 1.0 09 May 2018 Acceptability Questionnaire 1.0 20 October 2022 ACE 1.0 23 November 2022 AQ 1.2 19 June 2018 ASRS 1.0 01 February 2023 ASSIST 1.0 02 August 2016 BPNS 1.0 21 December 2016 CSS 1.0 18 October 2022 Demographics 1.0 01 November 2022 Functioning Probes 1.0 01 February 2023 GAD-7 1.0 18 July 2017 GF Role 1.0 01 February 2023 GFS Social 1.0 01 February 2023 GSES 1.0 01 February 2023 Implementation Interview Guide 1.0 20 October 2022 K10 1.1 21 August 2017 NSSR-VF 1.0 01 February 2023 PANSS 1.1 26 May 2016 PCL-5 1.1 29 November 2022 PDQ-D 1.1 18 January 2018 Strengths Use Scale <td></td> <td></td> <td>-</td>			-
SCID-5 Diagnoses 1.0 09 May 2018 Acceptability Questionnaire 1.0 20 October 2022 ACE 1.0 23 November 2022 AQ 1.2 19 June 2018 ASRS 1.0 01 February 2023 ASSIST 1.0 02 August 2016 BPNS 1.0 21 December 2016 CSS 1.0 18 October 2022 Demographics 1.0 01 November 2022 Functioning Probes 1.0 01 February 2023 GAD-7 1.0 18 July 2017 GF Role 1.0 01 February 2023 GFS Social 1.0 01 February 2023 GSES 1.0 01 February 2023 Implementation Interview Guide 1.0 01 February 2023 K10 1.1 21 August 2017 NSSR-VF 1.0 01 February 2023 PANSS 1.1 26 May 2016 PCL-5 1.1 29 November 2022 PDQ-D 1.1 18 January 2018 SES 1.0 01 February 2023 SCID5 Overview 1.2 29 Jan		-	-
Acceptability Questionnaire 1.0 20 October 2022 ACE 1.0 23 November 2022 AQ 1.2 19 June 2018 ASRS 1.0 01 February 2023 ASSIST 1.0 02 August 2016 BPNS 1.0 21 December 2016 CSS 1.0 18 October 2022 Demographics 1.0 01 November 2022 Functioning Probes 1.0 01 February 2023 GAD-7 1.0 18 July 2017 GF Role 1.0 01 February 2023 GSES 1.0 01 February 2023 GSES 1.0 01 February 2023 Implementation Interview Guide 1.0 20 October 2022 K10 1.1 21 August 2017 NSSR-VF 1.0 01 February 2023 PANSS 1.1 26 May 2016 PCL-5 1.1 29 November 2022 PDQ-D 1.1 18 January 2018 RSES 1.0 01 February 2023 SCID5 Overview 1.2 29 January 2018 Strengths Use Scale 1.0 01 Fe		1.0	09 May 2018
ACE 1.0 23 November 2022 AQ 1.2 19 June 2018 ASRS 1.0 01 February 2023 ASSIST 1.0 02 August 2016 BPNS 1.0 21 December 2016 CSS 1.0 18 October 2022 Demographics 1.0 01 November 2022 Functioning Probes 1.0 01 February 2023 GAD-7 1.0 18 July 2017 GF Role 1.0 01 February 2023 GSES 1.0 01 February 2023 GSES 1.0 01 February 2023 Implementation Interview Guide 1.0 20 October 2022 K10 1.1 21 August 2017 NSSR-VF 1.0 01 February 2023 PANSS 1.1 26 May 2016 PCL-5 1.1 29 November 2022 PDQ-D 1.1 18 January 2018 RSES 1.0 01 February 2023 SCID5 Overview 1.2 29 January 2018 Strengths Use Scale 1.0 01 February 2023 VIA-72 1.0 26 July 2022 <td></td> <td>1.0</td> <td>·</td>		1.0	·
AQ 1.2 19 June 2018 ASRS 1.0 01 February 2023 ASSIST 1.0 02 August 2016 BPNS 1.0 21 December 2016 CSS 1.0 18 October 2022 Demographics 1.0 01 November 2022 Functioning Probes 1.0 01 February 2023 GAD-7 1.0 18 July 2017 GF Role 1.0 01 February 2023 GF Social 1.0 01 February 2023 GSES 1.0 01 February 2023 Implementation Interview Guide 1.0 20 October 2022 K10 1.1 21 August 2017 NSSR-VF 1.0 01 February 2023 PANSS 1.1 26 May 2016 PCL-5 1.1 29 November 2022 PDQ-D 1.1 18 January 2018 RSES 1.0 01 February 2023 SCID5 Overview 1.2 29 January 2018 Strengths Use Scale 1.0 01 February 2023 VIA-72 1.0 26 July 2022 WHODAS 2.0 1.0 15 January 2018 </td <td></td> <td></td> <td></td>			
ASRS 1.0 01 February 2023 ASSIST 1.0 02 August 2016 BPNS 1.0 21 December 2016 CSS 1.0 18 October 2022 Demographics 1.0 01 November 2022 Functioning Probes 1.0 01 February 2023 GAD-7 1.0 18 July 2017 GF Role 1.0 01 February 2023 GF Social 1.0 01 February 2023 GSES 1.0 01 February 2023 Implementation Interview Guide 1.0 20 October 2022 K10 1.1 21 August 2017 NSSR-VF 1.0 01 February 2023 PANSS 1.1 26 May 2016 PCL-5 1.1 29 November 2022 PDQ-D 1.1 18 January 2018 RSES 1.0 01 February 2023 SCID5 Overview 1.2 29 January 2018 Strengths Use Scale 1.0 01 February 2023 VIA-72 1.0 26 July 2022 WHODAS 2.0 1.0 15 January 2018			
ASSIST 1.0 02 August 2016 BPNS 1.0 21 December 2016 CSS 1.0 18 October 2022 Demographics 1.0 01 November 2022 Functioning Probes 1.0 01 February 2023 GAD-7 1.0 18 July 2017 GF Role 1.0 01 February 2023 GF Social 1.0 01 February 2023 GSES 1.0 01 February 2023 Implementation Interview Guide 1.0 20 October 2022 K10 1.1 21 August 2017 NSSR-VF 1.0 01 February 2023 PANSS 1.1 26 May 2016 PCL-5 1.1 29 November 2022 PDQ-D 1.1 18 January 2018 RSES 1.0 01 February 2023 SCID5 Overview 1.2 29 January 2018 Strengths Use Scale 1.0 01 February 2023 VIA-72 1.0 26 July 2022 WHODAS 2.0 1.0 15 January 2018			
BPNS 1.0 21 December 2016 CSS 1.0 18 October 2022 Demographics 1.0 01 November 2022 Functioning Probes 1.0 01 February 2023 GAD-7 1.0 18 July 2017 GF Role 1.0 01 February 2023 GF Social 1.0 01 February 2023 GSES 1.0 01 February 2023 Implementation Interview Guide 1.0 20 October 2022 K10 1.1 21 August 2017 NSSR-VF 1.0 01 February 2023 PANSS 1.1 26 May 2016 PCL-5 1.1 29 November 2022 PDQ-D 1.1 18 January 2018 RSES 1.0 01 February 2023 SCID5 Overview 1.2 29 January 2018 Strengths Use Scale 1.0 01 February 2023 VIA-72 1.0 26 July 2022 WHODAS 2.0 1.0 15 January 2018		1.0	•
CSS 1.0 18 October 2022 Demographics 1.0 01 November 2022 Functioning Probes 1.0 01 February 2023 GAD-7 1.0 18 July 2017 GF Role 1.0 01 February 2023 GF Social 1.0 01 February 2023 GSES 1.0 01 February 2023 Implementation Interview Guide 1.0 20 October 2022 K10 1.1 21 August 2017 NSSR-VF 1.0 01 February 2023 PANSS 1.1 26 May 2016 PCL-5 1.1 29 November 2022 PDQ-D 1.1 18 January 2018 RSES 1.0 01 February 2023 SCID5 Overview 1.2 29 January 2018 Strengths Use Scale 1.0 01 February 2023 VIA-72 1.0 26 July 2022 WHODAS 2.0 1.0 15 January 2018			_
Demographics 1.0 01 November 2022 Functioning Probes 1.0 01 February 2023 GAD-7 1.0 18 July 2017 GF Role 1.0 01 February 2023 GF Social 1.0 01 February 2023 GSES 1.0 01 February 2023 Implementation Interview Guide 1.0 20 October 2022 K10 1.1 21 August 2017 NSSR-VF 1.0 01 February 2023 PANSS 1.1 26 May 2016 PCL-5 1.1 29 November 2022 PDQ-D 1.1 18 January 2018 RSES 1.0 01 February 2023 SCID5 Overview 1.2 29 January 2018 Strengths Use Scale 1.0 01 February 2023 VIA-72 1.0 26 July 2022 WHODAS 2.0 1.0 15 January 2018			•
Functioning Probes 1.0 01 February 2023 GAD-7 1.0 18 July 2017 GF Role 1.0 01 February 2023 GF Social 1.0 01 February 2023 GSES 1.0 01 February 2023 Implementation Interview Guide 1.0 20 October 2022 K10 1.1 21 August 2017 NSSR-VF 1.0 01 February 2023 PANSS 1.1 26 May 2016 PCL-5 1.1 29 November 2022 PDQ-D 1.1 18 January 2018 RSES 1.0 01 February 2023 SCID5 Overview 1.2 29 January 2018 Strengths Use Scale 1.0 01 February 2023 VIA-72 1.0 26 July 2022 WHODAS 2.0 1.0 15 January 2018	Demographics		•
GAD-7 1.0 18 July 2017 GF Role 1.0 01 February 2023 GF Social 1.0 01 February 2023 GSES 1.0 01 February 2023 Implementation Interview Guide 1.0 20 October 2022 K10 1.1 21 August 2017 NSSR-VF 1.0 01 February 2023 PANSS 1.1 26 May 2016 PCL-5 1.1 29 November 2022 PDQ-D 1.1 18 January 2018 RSES 1.0 01 February 2023 SCID5 Overview 1.2 29 January 2018 Strengths Use Scale 1.0 01 February 2023 VIA-72 1.0 26 July 2022 WHODAS 2.0 1.0 15 January 2018		1.0	01 February 2023
GF Role 1.0 01 February 2023 GF Social 1.0 01 February 2023 GSES 1.0 01 February 2023 Implementation Interview Guide 1.0 20 October 2022 K10 1.1 21 August 2017 NSSR-VF 1.0 01 February 2023 PANSS 1.1 26 May 2016 PCL-5 1.1 29 November 2022 PDQ-D 1.1 18 January 2018 RSES 1.0 01 February 2023 SCID5 Overview 1.2 29 January 2018 Strengths Use Scale 1.0 01 February 2023 VIA-72 1.0 26 July 2022 WHODAS 2.0 1.0 15 January 2018		1.0	•
GF Social 1.0 01 February 2023 GSES 1.0 01 February 2023 Implementation Interview Guide 1.0 20 October 2022 K10 1.1 21 August 2017 NSSR-VF 1.0 01 February 2023 PANSS 1.1 26 May 2016 PCL-5 1.1 29 November 2022 PDQ-D 1.1 18 January 2018 RSES 1.0 01 February 2023 SCID5 Overview 1.2 29 January 2018 Strengths Use Scale 1.0 01 February 2023 VIA-72 1.0 26 July 2022 WHODAS 2.0 1.0 15 January 2018	GF Role	1.0	•
Implementation Interview Guide 1.0 20 October 2022 K10 1.1 21 August 2017 NSSR-VF 1.0 01 February 2023 PANSS 1.1 26 May 2016 PCL-5 1.1 29 November 2022 PDQ-D 1.1 18 January 2018 RSES 1.0 01 February 2023 SCID5 Overview 1.2 29 January 2018 Strengths Use Scale 1.0 01 February 2023 VIA-72 1.0 26 July 2022 WHODAS 2.0 1.0 15 January 2018	GF Social	1.0	•
K10 1.1 21 August 2017 NSSR-VF 1.0 01 February 2023 PANSS 1.1 26 May 2016 PCL-5 1.1 29 November 2022 PDQ-D 1.1 18 January 2018 RSES 1.0 01 February 2023 SCID5 Overview 1.2 29 January 2018 Strengths Use Scale 1.0 01 February 2023 VIA-72 1.0 26 July 2022 WHODAS 2.0 1.0 15 January 2018	GSES	1.0	01 February 2023
NSSR-VF 1.0 01 February 2023 PANSS 1.1 26 May 2016 PCL-5 1.1 29 November 2022 PDQ-D 1.1 18 January 2018 RSES 1.0 01 February 2023 SCID5 Overview 1.2 29 January 2018 Strengths Use Scale 1.0 01 February 2023 VIA-72 1.0 26 July 2022 WHODAS 2.0 1.0 15 January 2018	Implementation Interview Guide	1.0	20 October 2022
PANSS 1.1 26 May 2016 PCL-5 1.1 29 November 2022 PDQ-D 1.1 18 January 2018 RSES 1.0 01 February 2023 SCID5 Overview 1.2 29 January 2018 Strengths Use Scale 1.0 01 February 2023 VIA-72 1.0 26 July 2022 WHODAS 2.0 1.0 15 January 2018	K10	1.1	21 August 2017
PCL-5 1.1 29 November 2022 PDQ-D 1.1 18 January 2018 RSES 1.0 01 February 2023 SCID5 Overview 1.2 29 January 2018 Strengths Use Scale 1.0 01 February 2023 VIA-72 1.0 26 July 2022 WHODAS 2.0 1.0 15 January 2018	NSSR-VF	1.0	01 February 2023
PDQ-D 1.1 18 January 2018 RSES 1.0 01 February 2023 SCID5 Overview 1.2 29 January 2018 Strengths Use Scale 1.0 01 February 2023 VIA-72 1.0 26 July 2022 WHODAS 2.0 1.0 15 January 2018	PANSS	1.1	26 May 2016
RSES 1.0 01 February 2023 SCID5 Overview 1.2 29 January 2018 Strengths Use Scale 1.0 01 February 2023 VIA-72 1.0 26 July 2022 WHODAS 2.0 1.0 15 January 2018		1.1	·
RSES 1.0 01 February 2023 SCID5 Overview 1.2 29 January 2018 Strengths Use Scale 1.0 01 February 2023 VIA-72 1.0 26 July 2022 WHODAS 2.0 1.0 15 January 2018	PDQ-D	1.1	18 January 2018
Strengths Use Scale 1.0 01 February 2023 VIA-72 1.0 26 July 2022 WHODAS 2.0 1.0 15 January 2018		1.0	01 February 2023
Strengths Use Scale 1.0 01 February 2023 VIA-72 1.0 26 July 2022 WHODAS 2.0 1.0 15 January 2018	SCID5 Overview	1.2	29 January 2018
VIA-72 1.0 26 July 2022 WHODAS 2.0 1.0 15 January 2018	Strengths Use Scale	1.0	·
WHODAS 2.0 1.0 15 January 2018		1.0	26 July 2022
WHOQOL-BREF 1.1 17 January 2017	WHODAS 2.0	1.0	
	WHOQOL-BREF	1.1	17 January 2017

Governance Authorisation:

Governance Authorisation is required at each site participating in the study before the research project can commence at that site.

You are required to provide a copy of this HREC approval letter to the principal investigator for each site covered by this ethics approval for inclusion in the site specific assessment application.

Conditions of Ethics Approval:

- You are required to submit to the HREC:
 - An Annual Progress Report (that covers all sites listed on approval) for the duration of the project. This report is due by 31 March each year. Continuation of ethics approval is contingent on submission of an annual report being submitted by 31 March each year. Failure to comply with this requirement may result in suspension/withdrawal of the project by the HREC.
 - A comprehensive Final Report upon completion of the project.
- Submit to the reviewing HREC for approval any proposed amendments to the project including any proposed changes to the Protocol, Participant Information and Consent Form/s and the Investigator Brochure.
- Notify the reviewing HREC of any adverse events that have a material impact on the conduct of the research in accordance with the NHMRC's Safety Monitoring and Reporting in Clinical Trials Involving Therapeutic Goods (2016) guideline.
- Notify the reviewing HREC of your inability to continue as Coordinating Principal Investigator.
- Notify the reviewing HREC of the failure to commence the study within 12 months of the HREC
 approval date or if a decision is taken to end the study at any of the sites prior to the expected
 date of completion.
- Notify the reviewing HREC of any matters which may impact the conduct of the project.
- If your project involves radiation, you are legally obliged to conduct your research in accordance
 with the Australian Radiation Protection and Nuclear Safety Agency Code of Practice 'Exposure of
 Humans to Ionizing Radiation for Research Purposes' Radiation Protection series Publication No.8
 (May 2005)(ARPANSA Code).

Please note: Template forms for reporting Amendments, safety reporting, Annual/Final reports, etc. can be accessed from: https://www2.health.vic.gov.au/about/clinical-trials-and-research/clinical-trial-research/monitoring-reporting

NSW sites:

If your trial includes participants in NSW who may be incapable of providing valid consent to participate for themselves, the HREC suggest that you make yourself aware of the provisions of the *Medical Treatment Planning and Decisions Act 2016*. Prior to commencing your trial in NSW, you may need to make an application to the NSW Civil and Administrative Tribunal (NCAT) for approval for your trial to proceed as well as to provide direction on the appropriate consent mechanism. Please note that the Act contains serious penalties for conducting clinical trial research on non-competent participants without proper authorisation.

The HREC may conduct an audit of the project at any time.

Yours sincerely,

Prof Peter Colman

Chair – Royal Melbourne Hospital Human Research Ethics Committee (HREC)